Eagle Pharmaceuticals (NASDAQ: EGRX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
Valuation & Earnings
This table compares Eagle Pharmaceuticals and Assembly Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Eagle Pharmaceuticals||$189.48 million||4.58||$81.45 million||$6.20||9.38|
|Assembly Biosciences||N/A||N/A||-$44.26 million||($2.97)||-14.91|
This is a breakdown of current ratings and price targets for Eagle Pharmaceuticals and Assembly Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Eagle Pharmaceuticals currently has a consensus price target of $62.33, suggesting a potential upside of 7.18%. Assembly Biosciences has a consensus price target of $42.50, suggesting a potential downside of 4.02%. Given Eagle Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Eagle Pharmaceuticals is more favorable than Assembly Biosciences.
Volatility and Risk
Eagle Pharmaceuticals has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
This table compares Eagle Pharmaceuticals and Assembly Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
62.1% of Assembly Biosciences shares are held by institutional investors. 19.5% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 19.6% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Eagle Pharmaceuticals beats Assembly Biosciences on 8 of the 11 factors compared between the two stocks.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.